BridgeBio Pharma, Inc. — Director's Dealing 2025

Dec 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-12-12

Reporting Person: Kumar Neil (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-12	Common Stock	M	60975	—	Acquired	289751	Direct
2025-12-12	Common Stock	F	30964	$75.15	Disposed	258787	Direct
2025-12-15	Common Stock	S	28311	$74.5997	Disposed	230476	Direct
2025-12-15	Common Stock	S	1700	$75.2412	Disposed	228776	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-12	Restricted Stock Units	$	M	60975	Disposed		Common Stock (60975)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	755686	Indirect
Common Stock	4558447	Indirect

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 60,975 shares of Common Stock underlying the Reporting Person's RSUs.

F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F4: Represents the weighted average sale price of the shares sold from $74.12 to $75.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F5: Represents the weighted average sale price of the shares sold from $75.13 to $75.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F6: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

F7: The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.